Assembly Biosciences, Inc. (ASMB)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
20.34 USD
-2.43
(-10.672%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:55 a.m. EDT
The investment case for Assembly Biosciences is currently paralyzed by a stark disconnect between its massive cash hoard and its inability to generate commercial revenue. While the company sits on over $320 million in cash with negligible debt, offering a theoretical safety net, the fundamentals reveal a business burning through capital with negative operating cash flow and no path to profitability visible in the trailing twelve months. The stock has suffered a brutal multi-year decline, dropping nearly 80% from its peak, which reflects the market's deep skepticism regarding the commercial viability of its pipeline despite recent clinical progress. The recent price action shows the stock trading well below its moving averages, confirming a persistent downtrend. Although analysts have raised targets citing a strategic partnership with Gilead that de-risks certain programs, this is insufficient to overcome the structural lack of earnings and the history of missed estimates. For investors, this remains a speculative gamble on a future cure rather than a sound investment in a profitable enterprise. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.139726 |
| AutoTheta | 0.158386 |
| AutoETS | 0.158792 |
| MSTL | 0.159232 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 29.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.102 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.769 |
| Revenue per Share | 4.574 |
| Market Cap | 414,134,528 |
| Trailing P/E | 19.56 |
| Forward P/E | -7.90 |
| Beta | 1.16 |
| Profit Margins | -0.06% |
| Website | https://www.assemblybio.com |
As of Oct. 10, 2026, 5:55 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts (strikes 17.5 and 20.0) and significant call volume at strikes 40 and 45, indicating a 'long gamma' setup where traders bet on volatility expansion rather than a specific directional breakout. The implied volatility skew suggests fear of a downside gap, while the call activity hints at a potential catalyst-driven rally, creating a polarized sentiment typical of biotech pre-data environments.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.19795704 |
| Address1 | Two Tower Place |
| Address2 | 7th Floor |
| All Time High | 1,260.0 |
| All Time Low | 7.68 |
| Ask | 26.21 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 261,800 |
| Average Daily Volume3 Month | 281,271 |
| Average Volume | 281,271 |
| Average Volume10Days | 261,800 |
| Beta | 1.157 |
| Bid | 16.07 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 15.398 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.34 |
| Current Ratio | 13.989 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 22.64 |
| Day Low | 20.28 |
| Debt To Equity | 0.769 |
| Display Name | Assembly Biosciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,510,400 |
| Ebitda | -8,688,000 |
| Ebitda Margins | -0.11608 |
| Enterprise To Ebitda | -11.064 |
| Enterprise To Revenue | 1.284 |
| Enterprise Value | 96,123,520 |
| Eps Current Year | -0.11774 |
| Eps Forward | -2.57377 |
| Eps Trailing Twelve Months | 1.04 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.5408 |
| Fifty Day Average Change | -8.2008 |
| Fifty Day Average Change Percent | -0.28733602 |
| Fifty Two Week Change Percent | -19.795704 |
| Fifty Two Week High | 39.71 |
| Fifty Two Week High Change | -19.369999 |
| Fifty Two Week High Change Percent | -0.48778644 |
| Fifty Two Week Low | 20.28 |
| Fifty Two Week Low Change | 0.059999466 |
| Fifty Two Week Low Change Percent | 0.0029585534 |
| Fifty Two Week Range | 20.28 - 39.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,292,596,200,000 |
| Float Shares | 9,174,281 |
| Forward Eps | -2.57377 |
| Forward P E | -7.902804 |
| Free Cashflow | -27,865,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 73 |
| Fullday Change | 0.36999893 |
| Fullday Change Percent | 1.8190705 |
| Fullday Price | 20.71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.14952 |
| Gross Profits | 11,191,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27656 |
| Held Percent Institutions | 0.69569 |
| Implied Shares Outstanding | 20,360,596 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,707,696,000 |
| Last Split Factor | 1:12 |
| Long Business Summary | Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. |
| Long Name | Assembly Biosciences, Inc. |
| Market | us_market |
| Market Cap | 414,134,528 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_99715344 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -42,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 518,177,168 |
| Number Of Analyst Opinions | 5 |
| Open | 22.62 |
| Operating Cashflow | -38,481,000 |
| Operating Margins | -0.47435 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 833 509 4583 |
| Pre Market Change | 0.36999893 |
| Pre Market Change Percent | 1.8190705 |
| Pre Market Price | 20.71 |
| Pre Market Time | 1,791,975,446 |
| Previous Close | 22.77 |
| Price Eps Current Year | -172.75352 |
| Price Hint | 2 |
| Price To Book | 1.3209507 |
| Price To Sales Trailing12 Months | 5.533229 |
| Profit Margins | -0.00056 |
| Quick Ratio | 13.789 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -2.43 |
| Regular Market Change Percent | -10.6719 |
| Regular Market Day High | 22.64 |
| Regular Market Day Low | 20.28 |
| Regular Market Day Range | 20.28 - 22.64 |
| Regular Market Open | 22.62 |
| Regular Market Previous Close | 22.77 |
| Regular Market Price | 20.34 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 305,630 |
| Return On Assets | -0.026719999 |
| Return On Equity | -0.00026 |
| Revenue Growth | 0.389 |
| Revenue Per Share | 4.574 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 20,360,596 |
| Shares Percent Shares Out | 0.13859999 |
| Shares Short | 2,822,392 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,120,055 |
| Short Name | Assembly Biosciences, Inc. |
| Short Percent Of Float | 0.18450001 |
| Short Ratio | 7.57 |
| Source Interval | 15 |
| State | CA |
| Symbol | ASMB |
| Target High Price | 62.0 |
| Target Low Price | 43.0 |
| Target Mean Price | 52.0 |
| Target Median Price | 52.0 |
| Total Cash | 320,360,992 |
| Total Cash Per Share | 15.734 |
| Total Debt | 2,350,000 |
| Total Revenue | 74,845,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.04 |
| Trailing P E | 19.557693 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 28.0372 |
| Two Hundred Day Average Change | -7.697201 |
| Two Hundred Day Average Change Percent | -0.27453527 |
| Type Disp | Equity |
| Volume | 305,630 |
| Website | https://www.assemblybio.com |
| Zip | 94,080 |